Agios rare blood disorder drug Pyrukynd sustains benefits in long term data
fpm/iStock via Getty Images Agios Pharmaceuticals (NASDAQ:AGIO) said long term data suggested that Pyrukynd led to improvements in hemoglobin, iron overload, transfusion burden and patient-reported outcomes, regardless of transfusion status in adults with pyruvate kinase (PK) deficiency. The company reported new data from an ongoing extension study of Pyrukynd (mitapivat) in patients who had participated … [Read more…]